Phreesia stock: fair value
PHRThe fair value of Phreesia under our model is $32.83, the price is 62% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $23.45 and expensive above $54.71 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $58.19 (cash-flow model) and $7.47 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $27.60, at 7.8% it would be $40.70.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (44.7).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 3.8%. Discounted at 8.8% (floor: government bond yield 3.8% plus 5 percentage points, since beta 1.11 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $58.19 per share: free cash flow for the next ten years, each year discounted to today at 8.8%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 8.8%) |
|---|---|---|---|---|
| 2027 | $85.7M | extrapolated at 46.0% | 0.9189 | $78.75M |
| 2028 | $114.26M | extrapolated at 33.3% | 0.8443 | $96.47M |
| 2029 | $142.22M | extrapolated at 24.5% | 0.7758 | $110.34M |
| 2030 | $168.22M | extrapolated at 18.3% | 0.7129 | $119.92M |
| 2031 | $191.68M | extrapolated at 13.9% | 0.6550 | $125.55M |
| 2032 | $212.59M | extrapolated at 10.9% | 0.6019 | $127.95M |
| 2033 | $231.27M | extrapolated at 8.8% | 0.5530 | $127.9M |
| 2034 | $248.15M | extrapolated at 7.3% | 0.5082 | $126.1M |
| 2035 | $263.68M | extrapolated at 6.3% | 0.4669 | $123.12M |
| 2036 | $278.26M | extrapolated at 5.5% | 0.4291 | $119.39M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $1.16B |
| Terminal value: cash flow 2036 × (1 + 3.8%) / (8.8% − 3.8%) | $5.78B |
| Present value of terminal value (× 0.4291) | $2.48B |
| Equity value (sum plus present value of terminal value) | $3.63B |
| Shares (diluted) | 62.46M |
| Value per share (equity value divided by shares) | $58.19 |
| Earnings per share, last twelve months | $0.17 |
| × 44.7 (industry P/E) | $7.47 |
| Fair value (average of both parts) | $32.83 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.